Search

Your search keyword '"Stuart, A."' showing total 2,666 results
Start Over Author "Stuart, A." Journal gastroenterology
2,666 results on '"Stuart, A."'

1. 223 IMMUNE CELL PHENOTYPING IN BARRETT'S ESOPHAGUS IN PATIENTS PRIOR AND AT TIME OF PROGRESSION

Author

Lin, Meng-Lay, Hickey, John W, Schürch, Christian M, Passman, Adam M, Carlotti, Emanuela, Devkumar, Shruthi, Hackett, Richard J, Rodriguez-Justo, Manuel, Novelli, Marco, Jansen, Marnix, Gascard, Philippe D, Tlsty, Thea D, and McDonald, Stuart A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Nutrition and Dietetics, Neurosciences, Paediatrics and Reproductive Medicine, Gastroenterology & Hepatology, Clinical sciences, Nutrition and dietetics
Published
2023

2. Tu1165: THE IMMUNE CELL MICROENVIRONMENT IS DIFFERENTIALLY-ALTERED ACCORDING TO DIVERSE EPITHELIAL LANDSCAPES IN THE PROGRESSION TO CANCER IN BARRETT OESOPHAGUS

Author

Lin, Meng-Lay, Hickey, John W, Schürch, Christian M, Carlotti, Emanuela, Passman, Adam M, Hackett, Richard J, Devkumar, Shruthi, Evans, James A, Gascard, Philippe D, Tlsty, Thea D, Ferri, Lorenzo E, Nolan, Garry P, and McDonald, Stuart A

Subjects
Clinical Sciences, Neurosciences, Paediatrics and Reproductive Medicine, Gastroenterology & Hepatology
Published
2022

5. Technical Review on the Management of Eosinophilic Esophagitis: A Report From the AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters

Author

Rank, Matthew A, Sharaf, Rajiv N, Furuta, Glenn T, Aceves, Seema S, Greenhawt, Matthew, Spergel, Jonathan M, Falck-Ytter, Yngve T, Dellon, Evan S, Institute, AGA, Chachu, Karen A, Day, Lukejohn, Lebwohl, Benjamin, Muniraj, Thiruvengadam, Patel, Amit, Peery, Anne F, Shah, Raj, Singh, Harminder, Singh, Siddharth, Spechler, Stuart J, Sultan, Shahnaz, Su, Grace L, Thrift, Aaron P, Weiss, Jennifer M, Weizman, Adam V, collaborators, Joint Task Force on Allergy-Immunology Practice Parameters, Bernstein, Jonathan A, Dinakar, Chitra, Golden, David BK, Khan, David A, Lieberman, Jay, Oppenheimer, John, Shaker, Marcus, Stukus, David R, Wallace, Dana V, and Wang, Julie

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Digestive Diseases, Nutrition, Food Allergies, Clinical Research, Administration, Topical, Adult, Advisory Committees, Age Factors, Allergy and Immunology, Child, Dilatation, Eosinophilic Esophagitis, Eosinophils, Esophagoscopy, Evidence-Based Medicine, Food Hypersensitivity, Food, Formulated, Gastroenterology, Glucocorticoids, Humans, Proton Pump Inhibitors, Societies, Medical, Treatment Outcome, United States, AGA Institute. Electronic address: clinicalpractice@gastro.org, Joint Task Force on Allergy-Immunology Practice Parameters collaborators. Electronic address: drdanawallace@gmail.com, AGA Institute, Joint Task Force on Allergy-Immunology Practice Parameters collaborators, Biologic Therapy, Corticosteroids, Dietary Therapy, Elemental Diet, Elimination Diet, Esophageal Dilation, Proton Pump Inhibitor, Swallowed Corticosteroids, Targeted Elimination Diet, Technical Review, Neurosciences, Paediatrics and Reproductive Medicine, Gastroenterology & Hepatology, Clinical sciences, Nutrition and dietetics
Abstract

Eosinophilic esophagitis (EoE) is a chronic inflammatory condition of the esophagus. Many new studies have been reported recently that describe EoE management. An expert panel was convened by the American Gastroenterological Association Institute and the Joint Task Force on Allergy-Immunology Practice Parameters to provide a technical review to be used as the basis for an updated clinical guideline. This technical review was developed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. Eighteen focused EoE management questions were considered, with 15 answered using the GRADE framework and 3 with a narrative summary. There is moderate certainty in the evidence that topical glucocorticosteroids effectively reduce esophageal eosinophil counts to

Published
2020

6. Pancreatitis-Associated PRSS1-PRSS2 Haplotype Alters T-Cell Receptor Beta (TRB) Repertoire More Strongly Than PRSS1 Expression

Author

Bellin, Melena D., Beilman, Greg, Brand, Randall E., Shelton Ohlsen, Celeste, Saloman, Jami L., Whitcomb, David C., Park, H.J., Lee, Kenneth K., Paniccia, Alessandro, Zureikat, Amer, Alkaade, Samer, Amann, Stephen, Anderson, Michelle A., Banks, Peter, Conwell, Darwin L., Cote, Gregory A., Forsmark, Christopher E., Gardner, Timothy B., Gelrud, Andres, Guda, Nalini M., Lewis, Michele D., Muniraj, Thiruvengadam, Papachristou, Georgios I., Romagnuolo, Joseph, Sandhu, Bimaljit S., Sherman, Stuart, Singh, Vikesh K., Slivka, Adam, Melbern Wilcox, Charles, Yadav, Dhiraj, Fu, Dongni, Blobner, Brandon M., Greer, Phil J., and Lafyatis, Robert

Published
2023
Full Text
View/download PDF

8. Late Recurrence of Barrett’s Esophagus After Complete Eradication of Intestinal Metaplasia is Rare: Final Report From Ablation in Intestinal Metaplasia Containing Dysplasia Trial

Author

Cotton, Cary C, Wolf, W Asher, Overholt, Bergein F, Li, Nan, Lightdale, Charles J, Wolfsen, Herbert C, Pasricha, Sarina, Wang, Kenneth K, Shaheen, Nicholas J, Group, AIM Dysplasia Trial, Sampliner, Richard E, Fleischer, David E, Sharma, Virender K, Eisen, Glenn M, Fennerty, M Brian, Hunter, John G, Bronner, Mary P, Goldblum, John R, Bennett, Ana E, Mashimo, Hiroshi, Rothstein, Richard I, Gordon, Stuart R, Edmundowicz, Steven A, Muthusamy, V Raman, Chang, Kenneth J, Kimmey, Michael B, Spechler, Stuart J, Siddiqui, Ali A, Souza, Rhonda F, Infantolino, Anthony, Dumot, John A, Falk, Gary W, Jobe, Blair A, Hawes, Robert H, Hoffman, Brenda J, Sharma, Prateek, and Chak, Amitabh

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Prevention, Clinical Trials and Supportive Activities, Clinical Research, Digestive Diseases, Cancer, Oral and gastrointestinal, Aged, Barrett Esophagus, Catheter Ablation, Disease Progression, Esophagus, Female, Follow-Up Studies, Humans, Incidence, Kaplan-Meier Estimate, Male, Metaplasia, Middle Aged, Mucous Membrane, Population Surveillance, Prospective Studies, Recurrence, Time Factors, AIM Dysplasia Trial Group, HGD, High Grade Dysplasia, LGD, Long-term Outcome, Low Grade Dysplasia, Prognostic Factor, Neurosciences, Paediatrics and Reproductive Medicine, Gastroenterology & Hepatology, Clinical sciences, Nutrition and dietetics
Abstract

Background & aimsThe goal of treatment for Barrett's esophagus (BE) with dysplasia is complete eradication of intestinal metaplasia (CEIM). The long-term durability of CEIM has not been well characterized, so the frequency and duration of surveillance are unclear. We report results from a 5-year follow-up analysis of patients with BE and dysplasia treated by radiofrequency ablation (RFA) in the randomized controlled Ablation of Intestinal Metaplasia Containing Dysplasia (AIM) trial.MethodsParticipants for the AIM Dysplasia trial (18-80 years old) were recruited from 19 sites in the United States and had endoscopic evidence of non-nodular dysplastic BE ≤8 cm in length. Subjects (n = 127) were randomly assigned (2:1 ratio) to receive either RFA (entire BE segment ablated circumferentially) or a sham endoscopic procedure; patients in the sham group were offered RFA treatment 1 year later, and all patients were followed for 5 years. We collected data on BE recurrence (defined as intestinal metaplasia in the tubular esophagus) and dysplastic BE recurrence among patients who achieved CEIM. We constructed Kaplan-Meier estimates and applied parametric survival analysis to examine proportions of patients without any recurrence and without dysplastic recurrence.ResultsOf 127 patients in the AIM Dysplasia trial, 119 received RFA and met inclusion criteria. Of those 119, 110 (92%) achieved CEIM. Over 401 person-years of follow-up (mean, 3.6 years per patient; range, 0.2-5.8 years), 35 of 110 (32%) patients had recurrence of BE or dysplasia, and 19 (17%) had dysplasia recurrence. The incidence rate of BE recurrence was 10.8 per 100 person-years overall (95% CI, 7.8-15.0); 8.3 per 100 person-years among patients with baseline low-grade dysplasia (95% CI, 4.9-14.0), and 13.5 per 100 person-years among patients with baseline high-grade dysplasia (95% CI 8.8-20.7). The incidence rate of dysplasia recurrence was 5.2 per 100 person-years overall (95% CI 3.3-8.2); 3.3 per 100 person-years among patients with baseline low-grade dysplasia (95% CI 1.5-7.2), and 7.3 per 100 person-years among patients with baseline high-grade dysplasia (95% CI 4.2-12.5). Neither BE nor dysplasia recurred at a constant rate. There was a greater probability of recurrence in the first year following CEIM than in the following 4 years combined.ConclusionsIn this analysis of prospective cohort data from the AIM Dysplasia trial, we found BE to recur after CEIM by RFA in almost one third of patients with baseline dysplastic disease; most recurrences occurred during the first year after CEIM. However, patients who achieved CEIM and remained BE free at 1 year after RFA had a low risk of BE recurrence. Studies are needed to determine when surveillance can be decreased or discontinued; our study did not identify any BE or dysplasia recurrence after 4 years of surveillance.

Published
2017

9. Clonal Transitions and Phenotypic Evolution in Barrett’s Esophagus

Author

Evans, James A., Carlotti, Emanuela, Lin, Meng-Lay, Hackett, Richard J., Haughey, Magnus J., Passman, Adam M., Dunn, Lorna, Elia, George, Porter, Ross J., McLean, Mairi H., Hughes, Frances, ChinAleong, Joanne, Woodland, Philip, Preston, Sean L., Griffin, S. Michael, Lovat, Laurence, Rodriguez-Justo, Manuel, Huang, Weini, Wright, Nicholas A., Jansen, Marnix, and McDonald, Stuart A.C.

Published
2022
Full Text
View/download PDF

10. Competence in Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography, From Training Through Independent Practice

Author

Wani, Sachin, Keswani, Rajesh N, Han, Samuel, Aagaard, Eva M, Hall, Matthew, Simon, Violette, Abidi, Wasif M, Banerjee, Subhas, Baron, Todd H, Bartel, Michael, Bowman, Erik, Brauer, Brian C, Buscaglia, Jonathan M, Carlin, Linda, Chak, Amitabh, Chatrath, Hemant, Choudhary, Abhishek, Confer, Bradley, Coté, Gregory A, Das, Koushik K, DiMaio, Christopher J, Dries, Andrew M, Edmundowicz, Steven A, El Chafic, Abdul Hamid, El Hajj, Ihab, Ellert, Swan, Ferreira, Jason, Gamboa, Anthony, Gan, Ian S, Gangarosa, Lisa M, Gannavarapu, Bhargava, Gordon, Stuart R, Guda, Nalini M, Hammad, Hazem T, Harris, Cynthia, Jalaj, Sujai, Jowell, Paul S, Kenshil, Sana, Klapman, Jason, Kochman, Michael L, Komanduri, Srinadh, Lang, Gabriel, Lee, Linda S, Loren, David E, Lukens, Frank J, Mullady, Daniel, Muthusamy, V Raman, Nett, Andrew S, Olyaee, Mojtaba S, Pakseresht, Kavous, Perera, Pranith, Pfau, Patrick, Piraka, Cyrus, Poneros, John M, Rastogi, Amit, Razzak, Anthony, Riff, Brian, Saligram, Shreyas, Scheiman, James M, Schuster, Isaiah, Shah, Raj J, Sharma, Rishi, Spaete, Joshua P, Singh, Ajaypal, Sohail, Muhammad, Sreenarasimhaiah, Jayaprakash, Stevens, Tyler, Tabibian, James H, Tzimas, Demetrios, Uppal, Dushant S, Urayama, Shiro, Vitterbo, Domenico, Wang, Andrew Y, Wassef, Wahid, Yachimski, Patrick, Zepeda-Gomez, Sergio, Zuchelli, Tobias, and Early, Dayna

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Biomedical Imaging, Clinical Research, Digestive Diseases, Cholangiopancreatography, Endoscopic Retrograde, Clinical Competence, Endosonography, Humans, Learning Curve, Prospective Studies, Quality Indicators, Health Care, Quality Indicators, Advanced Endoscopy Training, Learning Curves, The EUS and ERCP Skills Assessment Tool, Neurosciences, Paediatrics and Reproductive Medicine, Gastroenterology & Hepatology, Clinical sciences, Nutrition and dietetics
Abstract

Background & aimsIt is unclear whether participation in competency-based fellowship programs for endoscopic ultrasound (EUS) and endoscopic retrograde cholangiopancreatography (ERCP) results in high-quality care in independent practice. We measured quality indicator (QI) adherence during the first year of independent practice among physicians who completed endoscopic training with a systematic assessment of competence.MethodsWe performed a prospective multicenter cohort study of invited participants from 62 training programs. In phase 1, 24 advanced endoscopy trainees (AETs), from 20 programs, were assessed using a validated competence assessment tool. We used a comprehensive data collection and reporting system to create learning curves using cumulative sum analysis that were shared with AETs and trainers quarterly. In phase 2, participating AETs entered data into a database pertaining to every EUS and ERCP examination during their first year of independent practice, anchored by key QIs.ResultsBy the end of training, most AETs had achieved overall technical competence (EUS 91.7%, ERCP 73.9%) and cognitive competence (EUS 91.7%, ERCP 94.1%). In phase 2 of the study, 22 AETs (91.6%) participated and completed a median of 136 EUS examinations per AET and 116 ERCP examinations per AET. Most AETs met the performance thresholds for QIs in EUS (including 94.4% diagnostic rate of adequate samples and 83.8% diagnostic yield of malignancy in pancreatic masses) and ERCP (94.9% overall cannulation rate).ConclusionsIn this prospective multicenter study, we found that although competence cannot be confirmed for all AETs at the end of training, most meet QI thresholds for EUS and ERCP at the end of their first year of independent practice. This finding affirms the effectiveness of training programs. Clinicaltrials.gov ID NCT02509416.

Published
2018

11. Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference.

Author

Dellon, Evan, Liacouras, Chris, Molina-Infante, Javier, Furuta, Glenn, Spergel, Jonathan, Zevit, Noam, Spechler, Stuart, Attwood, Stephen, Straumann, Alex, Alexander, Jeffrey, Atkins, Dan, Arva, Nicoleta, Blanchard, Carine, Bonis, Peter, Book, Wendy, Capocelli, Kelley, Chehade, Mirna, Cheng, Edaire, Collins, Margaret, Davis, Carla, Dias, Jorge, Di Lorenzo, Carlo, Dohil, Ranjan, Dupont, Christophe, Falk, Gary, Ferreira, Cristina, Fox, Adam, Gonsalves, Nirmala, Gupta, Sandeep, Katzka, David, Kinoshita, Yoshikazu, Menard-Katcher, Calies, Kodroff, Ellyn, Metz, David, Miehlke, Stephan, Muir, Amanda, Mukkada, Vincent, Murch, Simon, Nurko, Samuel, Ohtsuka, Yoshikazu, Orel, Rok, Papadopoulou, Alexandra, Peterson, Kathryn, Philpott, Hamish, Putnam, Philip, Richter, Joel, Rosen, Rachel, Rothenberg, Marc, Schoepfer, Alain, Scott, Melissa, Shah, Neil, Sheikh, Javed, Souza, Rhonda, Strobel, Mary, Talley, Nicholas, Vaezi, Michael, Vandenplas, Yvan, Vieira, Mario, Walker, Marjorie, Wechsler, Joshua, Wershil, Barry, Wen, Ting, Yang, Guang-Yu, Hirano, Ikuo, Bredenoord, Albert, and Aceves, Seema

Subjects
Diagnosis, Eosinophilic Esophagitis, Esophageal Eosinophilia, Proton Pump Inhibitor, Algorithms, Consensus, Diagnostic Techniques, Digestive System, Eosinophilic Esophagitis, Gastroenterology, Humans, Predictive Value of Tests, Prognosis, Proton Pump Inhibitors
Abstract

BACKGROUND & AIMS: Over the last decade, clinical experiences and research studies raised concerns regarding use of proton pump inhibitors (PPIs) as part of the diagnostic strategy for eosinophilic esophagitis (EoE). We aimed to clarify the use of PPIs in the evaluation and treatment of children and adults with suspected EoE to develop updated international consensus criteria for EoE diagnosis. METHODS: A consensus conference was convened to address the issue of PPI use for esophageal eosinophilia using a process consistent with standards described in the Appraisal of Guidelines for Research and Evaluation II. Pediatric and adult physicians and researchers from gastroenterology, allergy, and pathology subspecialties representing 14 countries used online communications, teleconferences, and a face-to-face meeting to review the literature and clinical experiences. RESULTS: Substantial evidence documented that PPIs reduce esophageal eosinophilia in children, adolescents, and adults, with several mechanisms potentially explaining the treatment effect. Based on these findings, an updated diagnostic algorithm for EoE was developed, with removal of the PPI trial requirement. CONCLUSIONS: EoE should be diagnosed when there are symptoms of esophageal dysfunction and at least 15 eosinophils per high-power field (or approximately 60 eosinophils per mm2) on esophageal biopsy and after a comprehensive assessment of non-EoE disorders that could cause or potentially contribute to esophageal eosinophilia. The evidence suggests that PPIs are better classified as a treatment for esophageal eosinophilia that may be due to EoE than as a diagnostic criterion, and we have developed updated consensus criteria for EoE that reflect this change.

Published
2018

13. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease

Author

Sultan, Shahnaz, Cohen, Benjamin L., Chachu, Karen, Day, Lukejohn, Davitkov, Perica, Lebwohl, Benjamin, Levin, Theodore R., Patel, Amit, Peery, Anne F., Shah, Raj, Singh, Harminder, Singh, Siddharth, Spechler, Stuart J., Staller, Kyle, Thrift, Aaron P., Weiss, Jennifer M., Feuerstein, Joseph D., Ho, Edith Y., Shmidt, Eugenia, Falck-Ytter, Yngve, Sultan, Shanaz, and Terdiman, Jonathan P.

Published
2021
Full Text
View/download PDF

14. Functional Dyspepsia and Gastroparesis in Tertiary Care are Interchangeable Syndromes With Common Clinical and Pathologic Features

Author

Pasricha, Pankaj Jay, Bulat, Robert, Burns, Robert, Hernandez, Guillermo Barahona, McKnight, Megan, Kuo, Braden, Mendez, April, Staller, Kyle, Thurler, Andrea, Velez, Christopher, Silvernale, Casey, Parkman, Henry P., Malik, Zubair, Maurer, Alan, Palit, Amiya, McCallum, Richard W., Sarosiek, Irene, Vega, Natalia, Vasquez, Denise, Connery, Sean, Espino, Karina, Friedman, Marvin, Abell, Thomas, Stocker, Abigail, Cannon, Bridget, McElmurray, Lindsay, Cooper, Kelly, McBride, Catherine, Koch, Kenneth, Baxter, Lynn, Brown, Anya, Stuart, Paula, Abdullah, Amirah, Snape, William, DeVole, Nata, Earle, Karen, Kirkeby, Kjersti, Lee, Candice, Lin, Mimi, Troyer, Doug, von Bakonyi, Anna, Shulman, Robert, Chumpitazi, Bruno, Febo-Rodriguez, Liz, Hollier, John, Bouette, Cynthia, Charron, Heather, Nurko, Samuel, Wall, Stephanie, Kane, Madeline, Williams, Kent, Yossef-Salameh, Lina, Woodley, Frederick, Farrugia, Gianrico, Grover, Madhusudan, Bernard, Cheryl, Serrano, Jose, Hamilton, Frank, Hall, Sherry, James, Stephen, Torrance, Rebecca, Tonascia, James, Adamo, Margaret, Belt, Patricia, Dodge, John, Donithan, Michele, Isaacson, Milana, Lee, Linda, Meinert, Jill, Miriel, Laura, Sharkey, Emily, Smith, Jacqueline, Smith, Michael, Sternberg, Alice, Van Natta, Mark, Wagoner, Annette, Wilson, Laura, Yamada, Goro, Yates, Katherine, Pasricha, Pankaj J., Yates, Katherine P., Abell, Thomas L., Bernard, Cheryl E., Koch, Kenneth L., Chen, Jiande, Shulman, Robert J., and Miriel, Laura A.

Published
2021
Full Text
View/download PDF

16. From Birth to Overweight and Atopic Disease: Multiple and Common Pathways of the Infant Gut Microbiome

Author

Vu, Khanh, Lou, Wendy, Tun, Hein M., Konya, Theodore B., Morales-Lizcano, Nadia, Chari, Radha S., Field, Catherine J., Guttman, David S., Mandal, Rupasri, Wishart, David S., Azad, Meghan B., Becker, Allan B., Mandhane, Piush J., Moraes, Theo J., Lefebvre, Diana L., Sears, Malcolm R., Turvey, Stuart E., Subbarao, Padmaja, Scott, James A., and Kozyrskyj, Anita L.

Published
2021
Full Text
View/download PDF

18. Human Plasminogen Exacerbates Clostridioides difficile Enteric Disease and Alters the Spore Surface

Author

Awad, Milena M., Hutton, Melanie L., Quek, Adam J., Klare, William P., Mileto, Steven J., Mackin, Kate, Ly, Diane, Oorschot, Viola, Bosnjak, Marijana, Jenkin, Grant, Conroy, Paul J., West, Nick, Fulcher, Alex, Costin, Adam, Day, Christopher J., Jennings, Michael P., Medcalf, Robert L., Sanderson-Smith, Martina, Cordwell, Stuart J., Law, Ruby H.P., Whisstock, James C., and Lyras, Dena

Published
2020
Full Text
View/download PDF

21. Effects of Blended (Yellow) vs Forced Coagulation (Blue) Currents on Adverse Events, Complete Resection, or Polyp Recurrence After Polypectomy in a Large Randomized Trial

Author

Pohl, Heiko, Grimm, Ian S., Moyer, Matthew T., Hasan, Muhammad K., Pleskow, Douglas, Elmunzer, B. Joseph, Khashab, Mouen A., Sanaei, Omid, Al-Kawas, Firas H., Gordon, Stuart R., Mathew, Abraham, Levenick, John M., Aslanian, Harry R., Antaki, Fadi, von Renteln, Daniel, Crockett, Seth D., Rastogi, Amit, Gill, Jeffrey A., Law, Ryan J., Elias, Pooja A., Pellise, Maria, Mackenzie, Todd A., and Rex, Douglas K.

Published
2020
Full Text
View/download PDF

22. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

Author

Taylor, Rod S., Taylor, Rebecca J., Bayliss, Sue, Hagström, Hannes, Nasr, Patrik, Schattenberg, Jorn M., Ishigami, Masatoshi, Toyoda, Hidenori, Wai-Sun Wong, Vincent, Peleg, Noam, Shlomai, Amir, Sebastiani, Giada, Seko, Yuya, Bhala, Neeraj, Younossi, Zobair M., Anstee, Quentin M., McPherson, Stuart, and Newsome, Philip N.

Published
2020
Full Text
View/download PDF

23. Technical Review on the Management of Eosinophilic Esophagitis: A Report From the AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters

Author

Chachu, Karen A., Day, Lukejohn, Lebwohl, Benjamin, Muniraj, Thiruvengadam, Patel, Amit, Peery, Anne F., Shah, Raj, Singh, Harminder, Singh, Siddharth, Spechler, Stuart J., Sultan, Shahnaz, Su, Grace L., Thrift, Aaron P., Weiss, Jennifer M., Weizman, Adam V., Bernstein, Jonathan A., Dinakar, Chitra, Golden, David B.K., Khan, David A., Lieberman, Jay, Oppenheimer, John, Shaker, Marcus, Stukus, David R., Wallace, Dana V., Wang, Julie, Rank, Matthew A., Sharaf, Rajiv N., Furuta, Glenn T., Aceves, Seema S., Greenhawt, Matthew, Spergel, Jonathan M., Falck-Ytter, Yngve T., and Dellon, Evan S.

Published
2020
Full Text
View/download PDF

24. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis

Author

Chachu, Karen A., Day, Lukejohn, Lebwohl, Benjamin, Muniraj, Thiruvengadam, Patel, Amit, Peery, Anne F., Shah, Raj, Singh, Harminder, Singh, Siddharth, Spechler, Stuart J., Sultan, Shahnaz, Su, Grace L., Thrift, Aaron P., Weiss, Jennifer M., Weizman, Adam V., Bernstein, Jonathan A., Dinakar, Chitra, Golden, David B.K., Khan, David A., Lieberman, Jay, Oppenheimer, John, Shaker, Marcus, Wallace, Dana V., Wang, Julie, Hirano, Ikuo, Falck-Ytter, Yngve T., Rank, Matthew A., Stollman, Neil H., Wang, Kenneth, Stukus, David R., Greenhawt, Matthew, Sharaf, Rajiv N., Chan, Edmond S., Furuta, Glenn, Dellon, Evan, Spergel, Jonathan, Aceves, Seema, Falck-Ytter, Yngve, and Sharaf, Rajiv

Published
2020
Full Text
View/download PDF

26. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis

Author

Chachu, Karen, Day, Lukejohn, Lebwohl, Benjamin, Muniraj, Thiruvengadam, Patel, Amit, Peery, Anne F., Shah, Raj, Sultan, Shahnaz, Singh, Harminder, Singh, Siddharth, Spechler, Stuart, Su, Grace, Thrift, Aaron P., Weiss, Jennifer M., Weizman, Adam V., Feuerstein, Joseph, Isaacs, Kim, Schneider, Yecheskel, Falck-Ytter, Yngve, Siddique, Shazia Mehmood, Allegretti, Jessica, Terdiman, Jonathan, Feuerstein, Joseph D., and Isaacs, Kim L.

Published
2020
Full Text
View/download PDF

28. HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease

Author

Patel, Vinod, Mazhar, Zia, Saich, Rebecca, Colleypriest, Ben, Tham, Tony C, Iqbal, Tariq H, Kaushik, Vishal, Murugesan, Senthil, Singh, Salil, Weaver, Sean, Preston, Cathryn, Butt, Assad, Smith, Melissa, Basude, Dharamveer, Beale, Amanda, Langlands, Sarah, Direkze, Natalie, Parkes, Miles, Torrente, Franco, De La Revella Negro, Juan, Ewen MacDonald, Chris, Evans, Stephen M, Gunasekera, Anton V J, Thakur, Alka, Elphick, David, Shenoy, Achuth, Nwokolo, Chuka U, Dhar, Anjan, Cole, Andrew T, Agrawal, Anurag, Bridger, Stephen, Doherty, Julie, Cooper, Sheldon C, de Silva, Shanika, Mowat, Craig, Mayhead, Phillip, Lees, Charlie, Jones, Gareth, Ahmad, Tariq, Hart, James W, Gaya, Daniel R, Russell, Richard K, Gervais, Lisa, Dunckley, Paul, Mahmood, Tariq, Banim, Paul J R, Sonwalkar, Sunil, Ghosh, Deb, Phillips, Rosemary H, Azaz, Amer, Sebastian, Shaji, Shenderey, Richard, Armstrong, Lawrence, Bell, Claire, Hariraj, Radhakrishnan, Matthews, Helen, Jafferbhoy, Hasnain, Selinger, Christian P, Zamvar, Veena, De Caestecker, John S, Willmott, Anne, Miller, Richard, Sathish Babu, Palani, Tzivinikos, Christos, Bloom, Stuart L, Chung-Faye, Guy, Croft, Nicholas M, Fell, John ME, Harbord, Marcus, Hart, Ailsa, Hope, Ben, Irving, Peter M, Lindsay, James O, Mawdsley, Joel E, McNair, Alistair, Monahan, Kevin J, Murray, Charles D, Orchard, Timothy, Paul, Thankam, Pollok, Richard, Shah, Neil, Bouri, Sonia, Johnson, Matt W, Modi, Anita, Dawa Kabiru, Kasamu, Baburajan, B K, Bhaduri, Bim, Adebayo Fagbemi, Andrew, Levison, Scott, Limdi, Jimmy K, Watts, Gill, Foley, Stephen, Ramadas, Arvind, MacFaul, George, Mansfield, John, Grellier, Leonie, Morris, Mary-Anne, Tremelling, Mark, Hawkey, Chris, Kirkham, Sian, Charlton, Charles PJ, Rodrigues, Astor, Simmons, Alison, Lewis, Stephen J, Snook, Jonathon, Tighe, Mark, Goggin, Patrick M, De Silva, Aminda N, Lal, Simon, Smith, Mark S, Panter, Simon, Cummings, Fraser, Dharmisari, Suranga, Carter, Martyn, Watts, David, Mahmood, Zahid, McLain, Bruce, Sen, Sandip, Pigott, Anna J, Hobday, David, Wesley, Emma, Johnston, Richard, Edwards, Cathryn, Beckly, John, Vani, Deven, Ramakrishnan, Subramaniam, Chaudhary, Rakesh, Trudgill, Nigel J, Cooney, Rachel, Bell, Andy, Prasad, Neeraj, Gordon, John N, Brookes, Matthew J, Li, Andy, Gore, Stephen, Sazonovs, Aleksejs, Kennedy, Nicholas A., Moutsianas, Loukas, Heap, Graham A., Rice, Daniel L., Reppell, Mark, Bewshea, Claire M., Chanchlani, Neil, Walker, Gareth J., Perry, Mandy H., McDonald, Timothy J., Lees, Charlie W., Cummings, J.R. Fraser, Mansfield, John C., Irving, Peter M., Barrett, Jeffrey C., McGovern, Dermot, Goodhand, James R., and Anderson, Carl A.

Published
2020
Full Text
View/download PDF

29. Late Recurrence of Barrett’s Esophagus After Complete Eradication of Intestinal Metaplasia is Rare: Final Report From Ablation in Intestinal Metaplasia Containing Dysplasia Trial

Author

Sampliner, Richard E., Fleischer, David E., Sharma, Virender K., Eisen, Glenn M., Fennerty, M. Brian, Hunter, John G., Bronner, Mary P., Goldblum, John R., Bennett, Ana E., Mashimo, Hiroshi, Rothstein, Richard I., Gordon, Stuart R., Edmundowicz, Steven A., Muthusamy, V. Raman, Chang, Kenneth J., Kimmey, Michael B., Spechler, Stuart J., Siddiqui, Ali A., Souza, Rhonda F., Infantolino, Anthony, Dumot, John A., Falk, Gary W., Jobe, Blair A., Hawes, Robert H., Hoffman, Brenda J., Sharma, Prateek, Chak, Amitabh, Cotton, Cary C., Wolf, W. Asher, Overholt, Bergein F., Li, Nan, Lightdale, Charles J., Wolfsen, Herbert C., Pasricha, Sarina, Wang, Kenneth K., and Shaheen, Nicholas J.

Published
2017
Full Text
View/download PDF

32. Clip Closure Prevents Bleeding After Endoscopic Resection of Large Colon Polyps in a Randomized Trial

Author

Pohl, Heiko, Grimm, Ian S., Moyer, Matthew T., Hasan, Muhammad K., Pleskow, Douglas, Elmunzer, B. Joseph, Khashab, Mouen A., Sanaei, Omid, Al-Kawas, Firas H., Gordon, Stuart R., Mathew, Abraham, Levenick, John M., Aslanian, Harry R., Antaki, Fadi, von Renteln, Daniel, Crockett, Seth D., Rastogi, Amit, Gill, Jeffrey A., Law, Ryan J., Elias, Pooja A., Pellise, Maria, Wallace, Michael B., Mackenzie, Todd A., and Rex, Douglas K.

Published
2019
Full Text
View/download PDF

33. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin

Author

Moayyedi, Paul, Eikelboom, John W., Bosch, Jackie, Connolly, Stuart J., Dyal, Leanne, Shestakovska, Olga, Leong, Darryl, Anand, Sonia S., Störk, Stefan, Branch, Kelley R.H., Bhatt, Deepak L., Verhamme, Peter B., O’Donnell, Martin, Maggioni, Aldo P., Lonn, Eva M., Piegas, Leopoldo S., Ertl, Georg, Keltai, Matyas, Bruns, Nancy Cook, Muehlhofer, Eva, Dagenais, Gilles R., Kim, Jae-Hyung, Hori, Masatsugu, Steg, P. Gabriel, Hart, Robert G., Diaz, Rafael, Alings, Marco, Widimsky, Petr, Avezum, Alvaro, Probstfield, Jeffrey, Zhu, Jun, Liang, Yan, Lopez-Jaramillo, Patricio, Kakkar, Ajay K., Parkhomenko, Alexander N., Ryden, Lars, Pogosova, Nana, Dans, Antonio L., Lanas, Fernando, Commerford, Patrick J., Torp-Pedersen, Christian, Guzik, Tomek J., Vinereanu, Dragos, Tonkin, Andrew M., Lewis, Basil S., Felix, Camilo, Yusoff, Khalid, Metsarinne, Kaj P., Fox, Keith A.A., and Yusuf, Salim

Published
2019
Full Text
View/download PDF

34. Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis

Author

Widjaja, Anissa A., Singh, Brijesh K., Adami, Eleonora, Viswanathan, Sivakumar, Dong, Jinrui, D’Agostino, Giuseppe A., Ng, Benjamin, Lim, Wei Wen, Tan, Jessie, Paleja, Bhairav S., Tripathi, Madhulika, Lim, Sze Yun, Shekeran, Shamini Guna, Chothani, Sonia P., Rabes, Anne, Sombetzki, Martina, Bruinstroop, Eveline, Min, Lio Pei, Sinha, Rohit A., Albani, Salvatore, Yen, Paul M., Schafer, Sebastian, and Cook, Stuart A.

Published
2019
Full Text
View/download PDF

36. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial

Author

Moayyedi, Paul, Eikelboom, John W., Bosch, Jackie, Connolly, Stuart J., Dyal, Leanne, Shestakovska, Olga, Leong, Darryl, Anand, Sonia S., Störk, Stefan, Branch, Kelly R.H., Bhatt, Deepak L., Verhamme, Peter B., O’Donnell, Martin, Maggioni, Aldo P., Lonn, Eva M., Piegas, Leopoldo S., Ertl, Georg, Keltai, Matyas, Cook Bruns, Nancy, Muehlhofer, Eva, Dagenais, Gilles R., Kim, Jae-Hyung, Hori, Masatsugu, Steg, P. Gabriel, Hart, Robert G., Diaz, Rafael, Alings, Marco, Widimsky, Petr, Avezum, Alvaro, Probstfield, Jeffrey, Zhu, Jun, Liang, Yan, Lopez-Jaramillo, Patricio, Kakkar, Ajay, Parkhomenko, Alexander N., Ryden, Lars, Pogosova, Nana, Dans, Antonio, Lanas, Fernando, Commerford, Patrick J., Torp-Pedersen, Christian, Guzik, Tomek, Vinereanu, Dragos, Tonkin, Andrew M., Lewis, Basil S., Felix, Camilo, Yusoff, Khalid, Metsarinne, Kaj, Fox, Keith A.A., and Yusuf, Salim

Published
2019
Full Text
View/download PDF

39. Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn’s Disease

Author

Al-Hawary, Mahmoud, Anupindi, Sudha, Baker, Mark E., Bruining, David, Darge, Kassa, Dillman, Jonathan, Einstein, David, Fidler, Jeff L., Fletcher, Joel G., Gee, Michael S., Grand, David, Guglielmo, Falvius, Hara, Amy K., Jaffe, Tracy A., Maglinte, Dean, Megibow, Alec, Park, Seong Ho, Platt, Joel, Podberesky, Daniel, Rimola, Jordi, Sahani, Dushyant V., Soto, Jorge, Taylor, Stuart A., Bruining, David H., Zimmermann, Ellen M., Loftus, Edward V., Jr., Sandborn, William J., Sauer, Cary G., and Strong, Scott A.

Published
2018
Full Text
View/download PDF

40. Aprepitant Has Mixed Effects on Nausea and Reduces Other Symptoms in Patients With Gastroparesis and Related Disorders

Author

Snape, William J., DeVole, Nata, Earle, Karen, Kirkeby, Kjersti, Lee, Candice, Lin, Mimi, Ponting, Katie, Yee, Gloria, Pasricha, Pankaj Jay, Clarke, John O., Stein, Ellen, Dhalla, Sameer, Kim, Yale, Nguyen, Linda Anh B., Garay, Gotzone, Orlando, Chiara, Parkman, Henry P., Mauer, Alan, Orthey, Perry, Palit, Amiya, McCallum, Richard W., Sarosiek, Irene, Connery, Sean, Gomez, Yvette, Romero, Roberta, Vega, Natalia, Alvarado, Ben, Abell, Thomas L., Hatter, Lisa, Howard, Ronna, Nowotny, Lindsay, Hasler, William L., Herman, William, Kraftson, Andrew, Rothberg, Amy E., Wootten, Sophanara, Koch, Kenneth L., Baxter, Lynn, Brown, Anya, Stuart, Paula, Culler, Samantha, Farrugia, Gianrico, Grover, Madhusudan, Bernard, Cheryl, Hamilton, Frank, Serrano, Jose, James, Stephen, Torrance, Rebecca, Hall, Sherry, Tonascia, James, Belt, Patricia, Dodge, John, Donithan, Michele, Hallinan, Erin, Isaacson, Milana, Lee, Linda A., May, Patrick K., Miriel, Laura, Sternberg, Alice, Van Natta, Mark, Wagoner, Annette, Wilson, Laura, Yates, Katherine P., Pasricha, Pankaj J., Stein, Ellen M., Miriel, Laura A., Van Natta, Mark L., and Hamilton, Frank A.

Published
2018
Full Text
View/download PDF

41. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial

Author

Loren Laine, Kenneth DeVault, Philip Katz, Stefan Mitev, John Lowe, Barbara Hunt, and Stuart Spechler

Subjects
Hepatology, Gastroenterology
Abstract

For decades, proton pump inhibitors (PPIs) have been the mainstay of treatment for erosive esophagitis. The potassium-competitive acid blocker vonoprazan provides more potent acid inhibition than PPIs, but data on its efficacy for erosive esophagitis are limited.Adults with erosive esophagitis were randomized to once-daily vonoprazan, 20 mg, or lansoprazole, 30 mg, for up to 8 weeks. Patients with healing were rerandomized to once-daily vonoprazan, 10 mg, vonoprazan, 20 mg, or lansoprazole, 15 mg, for 24 weeks. Primary end points, percentage with healing by week 8 endoscopy, and maintenance of healing at week 24 endoscopy, were assessed in noninferiority comparisons (noninferiority margins, 10%), with superiority analyses prespecified if noninferiority was demonstrated. Analyses of primary and secondary end points were performed using fixed-sequence testing procedures.Among 1024 patients in the healing phase, vonoprazan was noninferior to lansoprazole in the primary analysis and superior on the exploratory analysis of healing (92.9 vs 84.6%; difference, 8.3%; 95% confidence interval [CI], 4.5%-12.2%). Secondary analyses showed vonoprazan was noninferior in heartburn-free days (difference, 2.7%; 95% CI, -1.6% to 7.0%), and superior in healing Los Angeles Classification Grade C/D esophagitis at week 2 (difference, 17.6%; 95% CI, 7.4%-27.4%). Among 878 patients in the maintenance phase, vonoprazan was noninferior to lansoprazole in the primary analysis and superior on the secondary analysis of maintenance of healing (20 mg vs lansoprazole: difference, 8.7%; 95% CI, 1.8%-15.5%; 10 mg vs lansoprazole: difference, 7.2%; 95% CI, 0.2%-14.1%) and secondary analysis of maintenance of healing Grade C/D esophagitis (20 mg vs lansoprazole: difference, 15.7%; 95% CI, 2.5%-28.4%; 10 mg vs lansoprazole: difference, 13.3%; 95% CI, 0.02%-26.1%).Vonoprazan was noninferior and superior to the PPI lansoprazole in healing and maintenance of healing of erosive esophagitis. This benefit was seen predominantly in more severe erosive esophagitis. (ClinicalTrials.gov: NCT04124926).

Published
2023
Full Text
View/download PDF

43. A Summary of the 2016 James W. Freston Conference of the American Gastroenterological Association: Intestinal Metaplasia in the Esophagus and Stomach: Origins, Differences, Similarities and Significance

Author

Spechler, Stuart J., Merchant, Juanita L., Wang, Timothy C., Chandrasoma, Parakrama, Fox, James G., Genta, Robert M., Goldenring, James R., Hayakawa, Yoku, Kuipers, Ernst J., Lund, Pauline K., McKeon, Frank, Mills, Jason C., Odze, Robert D., Peek, Richard M., Jr., Pham, Thai, Que, Jianwen, Rustgi, Anil K., Shaheen, Nicholas J., Shivdasani, Ramesh A., Souza, Rhonda F., Storz, Peter, Todisco, Andrea, Wang, David H., and Wright, Nicholas A.

Published
2017
Full Text
View/download PDF

44. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

Author

Jacobson, Ira M., Lawitz, Eric, Gane, Edward J., Willems, Bernard E., Ruane, Peter J., Nahass, Ronald G., Borgia, Sergio M., Shafran, Stephen D., Workowski, Kimberly A., Pearlman, Brian, Hyland, Robert H., Stamm, Luisa M., Svarovskaia, Evguenia, Dvory-Sobol, Hadas, Zhu, Yanni, Subramanian, G. Mani, Brainard, Diana M., McHutchison, John G., Bräu, Norbert, Berg, Thomas, Agarwal, Kosh, Bhandari, Bal Raj, Davis, Mitchell, Feld, Jordan J., Dore, Gregory J., Stedman, Catherine A.M., Thompson, Alexander J., Asselah, Tarik, Roberts, Stuart K., and Foster, Graham R.

Published
2017
Full Text
View/download PDF

50. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial

Author

Gane, Edward J., Kowdley, Kris V., Pound, David, Stedman, Catherine A.M., Davis, Mitchell, Etzkorn, Kyle, Gordon, Stuart C., Bernstein, David, Everson, Gregory, Rodriguez-Torres, Maribel, Tsai, Naoky, Khalid, Omer, Yang, Jenny C., Lu, Sophia, Dvory-Sobol, Hadas, Stamm, Luisa M., Brainard, Diana M., McHutchison, John G., Tong, Myron, Chung, Raymond T., Beavers, Kimberly, Poulos, John E., Kwo, Paul Y., and Nguyen, Mindie H.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results